Busy medical staff who treat patients suffering from bleeding can now wind down and reduce their stress levels thanks to a new comic based on Japanese manga style created by researchers at the London School of Hygiene & Tropical Medicine. Professor Ian Roberts devised a storyline to highlight the latest research into the life-saving benefits of tranexamic acid (TXA) in a way which he hopes will appeal to doctors, nurses and paramedics on the front-line of medicine.
The comic by professional artist Emma Vieceli and colourist Paul Duffield sets the scene in a busy emergency department as staff rush to treat people following two explosions.
As well as referencing established facts such as the importance of administering TXA within three hours of injury, the cartoon heroes also flag up new findings published on bmj.com which show that the drug can benefit a wide range of patients and should not be restricted to the most severe cases.
Amid the drama, doctors treating a patient say: "We have to do something about that bleeding. Get me an IV line and one gram of tranexamic acid now."
Prof Roberts said: "Health professionals are inundated with information and treatment guidelines so it can be difficult to keep track of all the latest developments. Our research has demonstrated how lives can be saved by this cheap and effective drug and the new paper shows that it can benefit all levels of severity if given within three hours of injury. We want to make sure that message comes through loud and clear and we hope this comic will get people interested and talking about TXA."
Cambridge-based Emma Vieceli, who is inspired by a fusion of many different styles of comic, said: "I am delighted to have been able to work on this project. It was an unusual challenge for me as I don't often get asked to illustrate medical themes. I hope people enjoy reading it and that patients benefit."
Advertisement
The potential for helping trauma patients was studied by Prof Roberts and an international team of collaborators in the CRASH-2 trial and is also currently being trialled in women at risk of haemorrhage in childbirth through the WOMAN trial.
Advertisement
Source-Eurekalert